Additionally, several cell functional assays wereconducted to characterize the phenotypic changes in lung cancer cellsgiven the OCIAD2 shRNA treatment, including MTT assay, colony formationassay, transwell migration, and invasion assays. This evidence concerns the gene OCIAD2 and lung carcinoma.